eligibility_summary
Eligibility: 18–75, consented, life expectancy ≥3 mo, histologically confirmed relapsed/refractory DLBCL, ≥1 measurable lesion (Lugano 2014), ECOG 0–2, adequate marrow/liver/renal (adjusted if liver/bone marrow involved). Exclude prior mitoxantrone, doxorubicin >360 mg/m2, HSCT ≤100 d, anticancer/clinical trial drugs ≤4 wks, hypersensitivity, uncontrolled systemic/cardiac disease, active HBV/HCV, HIV, other malignancy, CNS lymphoma, GI issues, pregnancy/lactation/no contraception, or if inappropriate.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single‑arm trial in relapsed/refractory DLBCL testing R‑MINE+X. R‑MINE: rituximab (anti‑CD20 monoclonal antibody, depletes B cells via CDC/ADCC), ifosfamide (alkylating DNA crosslinker), etoposide (topoisomerase II inhibitor), and mitoxantrone hydrochloride liposome (liposomal anthracenedione, DNA intercalator/topo II inhibitor with reduced cardiotoxicity). “X” is NGS subtype‑guided: MCD/BN2→orelabrutinib (covalent BTK inhibitor, blocks BCR→NF‑κB signaling), EZB→chidamide (oral HDAC inhibitor, epigenetic modulation, relevant to EZH2/EZB biology), A53/TP53‑mut→penpulimab (anti‑PD‑1 monoclonal antibody, restores T‑cell activity), other→lenalidomide (IMiD, cereblon‑mediated IKZF1/3 degradation, enhances T/NK, anti‑angiogenic). Targets: CD20+ malignant B cells, BCR/BTK‑NF‑κB pathway, histone deacetylases/epigenetic programs, PD‑1 on T cells, and tumor DNA replication/repair.